Biologic treatment response among adults with juvenile idiopathic arthritis: Results from the British society for rheumatology biologics register

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1905-1913

  McErlane, Flora ^a   Foster, Helen E ^b   Davies, Rebecca ^a   Lunt, Mark ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a,c   Hyrich, Kimme L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti TNF therapy; Disease activity; Juvenile idiopathic arthritis; Treatment outcome

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; DAS28; DISABILITY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; ONSET AGE; PRIORITY JOURNAL; REGISTER; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84887393466     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket248     Document Type: Article

References (41)

1. Symmons DP, Jones M, Osborne J et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975-80.
2. Foster HE, Marshall N, Myers A et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
3. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009;72(Suppl 1):20-5.
4. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
5. Lovell DJ, Giannini EH, ReiffA et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
6. Lovell DJ, ReiffA, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
7. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
8. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
9. Southwood TR, Foster HE, Davidson JE et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
10. Minden K, Niewerth M, Listing J et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
11. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
12. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
13. Watson K, Symmons D, Griffiths I et al. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64(Suppl 4):iv42-3.
14. Silman A, Symmons D, Scott DG et al. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003;62(Suppl 2):ii28-9.
15. Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
18. Goldsmith CH, Boers M, Bombardier C et al. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993;20:561-5.
19. van Gestel AM, van't Hof MA, van Rijswijk MH et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organisation/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
20. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
21. Singleton N, Bumpstead R, O'Brien M et al. Psychiatric morbidity among adults living in private households 2000. London: National Statistics, 2001.
22. Adib N, Hyrich K, Thornton J et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology 2008;47:991-5.
23. Minden K, Kiessling U, Listing J et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000;27:2256-63.
24. Oen K, Malleson PN, Cabral DA et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
25. Hyrich KL, Watson KD, Silman AJ et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
26. National Institute for Clinical Excellence. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology appraisal guidance no. 35. London: National Institute for Clinical Excellence, 2002.
27. Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
28. Taban M, Dupps WJ, Mandell B et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-50.
29. Ilowite N, Porras O, ReiffA et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37.
30. Nigrovic PA, Mannion M, Prince FH et al. Anakinra as firstline disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
31. Consolaro A, Ruperto N, Bazso A et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
32. Leeb BF, Andel I, Sautner J et al. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-60.
33. Hyrich K, Symmons D, Watson K et al. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006;65:895-8.
34. Saad AA, Ashcroft DM, Watson KD et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:697-705.
35. Fantini F, Gerloni V, Gattinara M et al. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003;30:579-84.
36. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 2002;41:1428-35.
37. Flato B, Lien G, Smerdel A et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
38. Arkela-Kautiainen M, Haapasaari J, Kautiainen H et al. Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Ann Rheum Dis 2005;64:875-80.
39. Gerhardt CA, McGoron KD, Vannatta K et al. Educational and occupational outcomes among young adults with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1385-91.
40. Minden K, Niewerth M, Zink A et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51:1407-15.
41. McDonagh JE. Transition of care from paediatric to adult rheumatology. Arch Dis Child 2007;92:802-7.